Pelage PP405 Phase 2a completed. 2/5/2026
Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Which 2026 hair‑loss treatments have the strongest evidence so far? (minoxidil/finasteride vs. clascoterone, PP405, Re:You’s NV‑623/624, AMP‑303, RU58841)
Minoxidil and finasteride are the only FDA-approved treatments for androgenetic alopecia, while newer treatments like clascoterone, PP405, NV-623/624, AMP-303, and RU58841 are still experimental with varying levels of evidence. Clascoterone shows the most promise due to strong human data, while AMP-303 has notable early human trial results; RU58841 lacks human data and remains experimental.
community 1 year on Oral Fin/min. Not feeling super great about it.
The user is unhappy with their hair regrowth after one year on oral finasteride and minoxidil, considering a hair transplant. Many suggest shaving the head or trying more aggressive treatments like RU58841, dutasteride, microneedling, and hair transplants.
community What are some promising/revolutionizing treatments that are in the pipeline/currently available?
The conversation discusses various hair loss treatments, including pyrilutamide, RU58841, topical dutasteride, oral minoxidil, and oral finasteride/dutasteride. It also mentions potential treatments like PP405, Verteporfin, GT20029, and AMP303.
community Now That PP405 Hype is Gone What is Everyone Coping with as the Next Cure?
People are discussing various hair loss treatments, including finasteride, minoxidil, RU58841, and new potential treatments like vdphl01, ABS-201, and KX-826. Some express hope in future developments like hair cloning and CRISPR, while others emphasize acceptance and sticking with current treatments.
community If PP405 works it will be fkn impossible to buy it.
PP405 is a potential hair loss treatment that may activate dormant hair follicles, but there are concerns about its effectiveness, cost, and side effects. Users discuss treatments like minoxidil, finasteride, and RU58841, expressing skepticism about PP405's long-term success and accessibility.
Related Research
6 / 6 resultsresearch Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
research CLINICAL UPDATES IN HAIR
This chapter reviews various antiandrogens and androgen inhibitors, detailing their mechanisms, uses, and side effects, with a focus on spironolactone, finasteride, dutasteride, and oral contraceptives.
research Investigational medications in the treatment of alopecia
This review discusses investigational treatments for androgenetic and chemotherapy-induced alopecia and reports no new clinical results, highlighting the need for further research.
research Minoxidil: effectiveness and prospects for use in the treatment of androgenetic alopecia
Minoxidil is an effective and safe treatment for common hair loss when applied to the skin, but more research is needed for optimal use.
research Тіе Modern treatment of androgenetic alopecia
This review examines the molecular mechanisms and current treatment options for androgenetic alopecia, highlighting potential future therapies but providing no new experimental findings.
research Андрогенетическая алопеция: патогенетические механизмы и подходы к лечению
This article reviews the pathophysiology and limited effectiveness of current treatments for androgenic alopecia, including finasteride, minoxidil, botulinum toxin A, and platelet-rich plasma, and highlights the need for new therapeutic approaches; it reports no new clinical findings.